Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Zoetis, with a price target of $215.00. The company’s shares closed last Friday at $147.35. Take advantage of ...

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 ...

Worse still, if you'd only held Zoetis stock for the past one, or three, or five years, you would have lost money. Zoetis ...

These two stocks come from completely different industries, but each could boost a long-term investor's returns.

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.